MBD4 and neoplasm: Recently, in next-generation sequencing studies, MBD4 somatic alterations, including point mutations and amplifications/deletions, have been identified, at a frequency ranging between 0.5%-8%, in a large series of unselected tumor samples (i.e. melanoma, ovarian, lung, esophagus and prostate cancers) [28–30].